If you are already a subscriber to this publication click here to read this item online in full.
If you wish to purchase the back-issue in which this item appeared, take a note of the Newsletter title and the month of publication and click here to visit the back-issues page from where you can order it.
Issue: May 2006, page: 10
Implant aids treatment of distressing condition
Following completion of the active clinical part of a Phase III study of an implant for treating central precocious puberty (CPP), or the early onset of puberty, manufacturer, Valera Pharmaceuticals Inc, plans to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) during this second quarter of 2006.